SCHEMBL7187031

SCHEMBL7187031

COc1c(Cl)c(C(=O)c2ccccc2)c(Cl)c(OC)c1[PH](=O)C(=O)c1c(C(F)(F)F)cccc1C(F)(F)F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.38
MRGPRX4 Q96LA9 3/20 0.35
NR1H2 P55055 1/20 0.35
NR1H3 Q13133 1/20 0.35
LMNA P02545 5/20 0.35
MAPT P10636 4/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
GAA P10253 2/20 0.34
RAB9A P51151 1/20 0.34
RORC P51449 2/20 0.33
PDK1 Q15118 1/20 0.33
PDK2 Q15119 1/20 0.33
PDK3 Q15120 1/20 0.33
PDK4 Q16654 1/20 0.33
EPHX2 P34913 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
KDM4E B2RXH2 2/20 0.33
NPSR1 Q6W5P4 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7182306 0.87 NR1H2 (0.36) MAOBMRGPRX4NR1H2NR1H3LMNA
SCHEMBL7735674 0.87 MAOB (0.36) MAOBMRGPRX4NR1H2NR1H3LMNA
SCHEMBL7181381 0.86 MRGPRX4 (0.37) MRGPRX4NR1H2NR1H3LMNAMAPT
SCHEMBL7187002 0.84 ALDH1A1 (0.40) LMNAMAPTMEN1KMT2AGAA
SCHEMBL7182465 0.83 CA12 (0.42) LMNAMAPTMEN1KMT2AGAA
SCHEMBL7182760 0.83 TAS1R3 (0.36) LMNAMAPTMEN1KMT2AGAA
SCHEMBL7178311 0.82 MRGPRX4 (0.39) MAOBMRGPRX4LMNAMAPTMEN1
SCHEMBL7722888 0.81 MRGPRX4 (0.40) MRGPRX4NR1H2NR1H3LMNAMAPT
SCHEMBL7189330 0.81 ALDH1A1 (0.38) LMNAMAPTMEN1KMT2AGAA
SCHEMBL7188332 0.81 TUBB4A (0.40) LMNAMAPTMEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MAOB 4189/4885MRGPRX4 3913/4885NR1H2 63/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MAOB 4319/4885MRGPRX4 4163/4885NR1H2 95/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.